Arcturus Therapeutics Holdings Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Arcturus Therapeutics Holdings Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- Israel
- Ticker symbol
- ARCT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001768224
Board of directors
-
Andy Sassine · Director · Chief Financial OfficerSince 2023
-
Edward W. Holmes · DirectorSince 2023
-
James F. Barlow · DirectorSince 2023
-
Jing L. Marantz · DirectorSince 2023
-
John Markels · DirectorSince 2023
-
Joseph E. Payne · Director · President and CEOSince 2023
- Since 2023
-
Moncef Slaoui · DirectorSince 2024
-
Peter C. Farrell · DirectorSince 2023
Chief executives
Joseph E. Payne
· President and CEO
Dates unknown
Board connections
4 of this board's directors also sit on 7 other boards.
- via John Markels and Moncef Slaoui
- via Magda Marquet
- via Peter C. Farrell
- via Magda Marquet
- via Magda Marquet
- via Peter C. Farrell
- via Magda Marquet
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 15, 2025 | Andy Sassine Director, Officer (Chief Financial Officer) | Open-market purchase | −1,238 | $16.56 | $20,501 |
| Oct 15, 2024 | Chivukula Pad Officer (Chief Scientific Officer & COO) | Open-market sale | −12,000 | $20.76 | $249,120 |
| Jun 14, 2024 | Jing L. Marantz Director | Option exercise | +3,131 | — | — |
| Jun 14, 2024 | Edward W. Holmes Director | Option exercise | +3,131 | — | — |
| Jun 14, 2024 | John Markels Director | Option exercise | +3,131 | — | — |
| Jun 14, 2024 | Magda Marquet Director | Option exercise | +3,131 | — | — |
| Jun 14, 2024 | James F. Barlow Director | Option exercise | +3,131 | — | — |
| Jun 14, 2024 | Peter C. Farrell Director | Option exercise | +3,131 | — | — |
| Jun 12, 2024 | Andy Sassine Director, Officer (Chief Financial Officer) | Open-market sale | −50,000 | $32.03 | $1,601,500 |
| Jun 5, 2024 | Chivukula Pad Officer (Chief Scientific Officer & COO) | Open-market sale | −114 | $45.00 | $5,130 |
| Jun 3, 2024 | Chivukula Pad Officer (Chief Scientific Officer & COO) | Open-market sale | −26,000 | $40.01 | $1,040,260 |
| Mar 25, 2024 | Chivukula Pad Officer (Chief Scientific Officer & COO) | Open-market sale | −17,435 | $35.02 | $610,574 |
| Mar 19, 2024 | Chivukula Pad Officer (Chief Scientific Officer & COO) | Open-market sale | −8,565 | $35.01 | $299,861 |
| Nov 1, 2023 | Chivukula Pad Officer (Chief Scientific Officer & COO) | Open-market sale | −5,000 | $18.72 | $93,600 |
| Oct 2, 2023 | Chivukula Pad Officer (Chief Scientific Officer & COO) | Open-market sale | −5,000 | $25.61 | $128,050 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.